pipette
ESEspañol

Bifidobacterium animalis subsp. lactis BL-99 ameliorates age-related intestinal hypomotility in older adults: a randomized controlled trial

Wen Zhao, Shaoqi Shi, Limian Zhou, Liang Zhao, Juan Chen, Yinghua Liu, Qi Zhang, Hao Zhang, Zhi Zhao, Chengying Zhang, Yixuan Li, Wei‐Lian Hung, Rong Liu, Dekui Jin, Ming Zhang, Guang Li, Xinjuan Liu, Xiaoxia Li, Shaoyang Ge, Zhaozhong Zeng, Yong Zhang, Hanglian Lan, Qiuyue Jiang, Yanling Hao, Jie Guo, Huiyuan Guo, Yuyang Zhao, Wei Xiong, Xiaokang Niu, Liwei Zhang, Jian He, Jingjing He, Ran Wang, Fazheng Ren

Peer-reviewed journalBold claims, read criticallyReal-world use

In the authors' words

The decay of smooth muscle contractility is a major trigger of aging-related intestinal hypomotility, which imposes a substantial healthcare burden. Despite this, effective targeted therapy for this condition remains unavailable. Here, we identified the probiotic Bifidobacterium animalis subsp. lactis BL-99 as a microbiota modulator that restores gut motility through the bile acid (BA)-mediated rescue of smooth muscle contractile function. In a randomized, double-blind clinical trial (ChiCTR2300077583, with the primary endpoint of whole-gut transit time [WGTT], and secondary endpoints including bowel movement frequency, symptom severity, and quality-of-life measures) and naturally aged mouse models, BL-99 intervention significantly reduced the WGTT and concurrently remodeled the gut microbiota. This suppressed bile salt hydrolase-expressing bacteria, which preserved conjugated BA pools, including taurochenodeoxycholic acid (TCDCA). Mechanistic investigations revealed that BL-99 was associated with enhanced expression of the serum response factor (SRF)–myocardin (Myocd) transcriptional axis in colonic smooth muscle cells (SMCs), restoring contractile apparatus components (e.g., α-SMA, SM-MHC). Crucially, TCDCA administration recapitulated BL-99 regulation of intestinal SMC contractile protein expression by inhibiting the PI3K/AKT pathway. Our findings established a microbiota-BA-SMC signaling axis that ameliorates age-related intestinal hypomotility, positioning both BL-99 and TCDCA as precision therapeutic candidates targeting SMC-related dysmotility. Here, in a randomized, double-blind clinical trial in older adults, the authors show that probiotic Bifidobacterium animalis subsp. lactis BL-99 intervention reduces whole-gut transit time and remodels the gut microbiota suppressing bile salt hydrolase-expressing bacteria, further revealing a mechanistic role of taurochenodeoxycholic acid in the phenotype.

Main resultThe abstract does not state a limitation.

Appeared: Thursday, October 8. Nature Communications. Peer-reviewed journal.

DOI: 10.1038/s41467-026-77524-x